GDM Biomarker Development Service

GDM Biomarker Development Service

Earlier detection of GDM may possibly prevent pregnancy complications. Thus, the identification of sensitive and specific biomarkers is important, which may offer potential for risk prediction and intervention strategies. Ace Therapeutics can provide researchers engaged in biomarkers development of GDM with more efficient function analysis and overall therapy services.

About GDM Biomarkers

The research on screening biomarkers in the early stage of GDM has gradually is important, involving markers related to the etiology and pathophysiology of GDM, metabolomics markers, etc. Routine GDM biomarkers (plasma glucose, insulin, C-peptide, homeostatic model assessment of insulin resistance, and sex hormone-binding globulin) can differentiate between healthy pregnant women and those with GDM.

Type of GDM Biomarkers

  • Anti-insulin Hormones
    There are some hormones with insulin-sensitizing properties which can be biomarkers of GDM, such as oxytocin, irisin, placental lactogen, FGF21.

Fig 2. Anti-insulin Hormones

  • Adipokine and Inflammatory Biomarkers
    The C-reactive protein (CRP), the highly sensitive C-reactive protein (hs-CRP), tumour necrosis factor alpha (TNF-α) and interleu-kin-6 (IL-6) are the main inflammatory cytokines increased in insulin resistance and GDM. Adipokine related to GDM mainly include leptin, adiponectin, visfatin, resistin, etc.

Immune spectrum in lean and obese adipose tissueImmune spectrum in lean and obese adipose tissue (Man, Kevin et al. 2022)

  • Other GDM Biomarkers
    Metabolites, microRNA or other biomolecules for GDM to complement traditional biomarkers.
Novel Biomarkers Description
Afamin Afamin is a vitamin E-binding protein found in human plasma, which plays a role in the antiapoptotic cellular processes associated with oxidative stress.
ANGPTL8 Angiopoietin-like protein 8 is involved in lipid and glucose homeostasis, and its concentrations were found to be higher under conditions of GDM than normal pregnancy.
Galanin Galanin is a neuropeptide that reduces insulin resistance and improves glucose uptake.
VAP-1 Vascular adhesion protein 1 (VAP-1) is a glycoprotein that plays a role in inflammation and oxidative stress.
FABP4 Fatty acid-binding protein 4 (FABP-4) is a protein highly expressed in adipocytes.
Fetuin-A or AHSG It is a glycoprotein that is produced by the liver and adipose tissue, and can be secreted by the placenta during pregnancy.
EVs Extracellular vesicles (EVs) are small vesicles released into the extracellular space with the ability to reach the blood circulation.
Maternal microbiota The microbiome also participate in the pathogenesis of several metabolic disorders, the composition of the maternal oral or gut microbiota could be a biomarker for GDM.

Our Services

Effective biomarkers are of great significance for early prediction of GDM. Ace Therapeutics can provide the biomarker development services for gestational diabetes mellitus. Our services include but not limited to the followings.

  • Discovering Hormones during Pregnancy Related to GDM.
  • Discovering Inflammatory and Adipokine Biomarkers.
  • Developing Metabolomics and MicroRNA Biomarkers.

Features of Our Services

Highly CustomizableHighly Customizable

One-stop ServicesOne-stop Services

High QualityHigh Quality

Professional TeamProfessional Team

Ace Therapeutics offers cost-effect and high-quality research services related to GDM therapy for our clients worldwide. Our assays are developed and processed with the highest standard and the results are delivered on time without compromising quality. Please feel free to contact us.


  1. McIntyre, H. D.; et al. Gestational diabetes mellitus. Nature Reviews Disease Primers. 2019, 5, 47.
  2. Dias, S.; et al. Molecular biomarkers for gestational diabetes mellitus. International journal of molecular sciences. 2018, 19(10), 2926.
  3. Man, Kevin et al. Resident and migratory adipose immune cells control systemic metabolism and thermogenesis. Cellular & molecular immunology vol. 19,3 (2022): 421-431.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
Related Services
Related Products
Contact Info
Copyright © Ace Therapeutics. All Rights Reserved.